1
|
Melgar P, Rodríguez-Laiz GP, Lluís N, Alcázar-López C, Franco-Campello M, Villodre C, Pascual S, Rodríguez-Soler M, Bellot P, Miralles C, Perdiguero M, Díaz M, Mas-Serrano P, Zapater P, Ramia JM, Lluís F. Textbook outcome among patients undergoing enhanced recovery after liver transplantation stratified by risk. A single-center retrospective observational cohort study. Int J Surg 2022; 99:106266. [PMID: 35182809 DOI: 10.1016/j.ijsu.2022.106266] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2021] [Revised: 01/01/2022] [Accepted: 02/09/2022] [Indexed: 02/07/2023]
Abstract
BACKGROUND & AIMS Liver transplantation (LT) is one of the most complex surgical procedures. Enhanced recovery after surgery (ERAS) aims to reduce the risk of postoperative complications. When patients achieve all desirable outcomes after a procedure, they are considered to have experienced a textbook outcome (TO). METHODS Two cohorts of patients undergoing low (n = 101) or medium risk (n = 15) LT were identified. The remaining patients (n = 65) were grouped separately. The ERAS protocol included pre-, intra-, and post-operative steps. TO was defined as the absence of complications, prolonged length of hospital stays, readmission and mortality during the first 90 days. RESULTS One third of patients who underwent ERAS after LT experienced a TO. On multivariable analysis, age (OR, 1.05 [95% CI, 1.01-1.09]; P = .02), and having hepatocellular carcinoma (OR, 2.83 [95% CI, 1.37-6.03]; P = .005) were individually associated with a greater probability of achieving a TO. Belonging to the cohorts of medium risk or outside the selection criteria was associated with a lower probability of achieving a TO (OR, 0.46 [96% CI, 0.22-0.93]; P = .03). Patients less likely to experience TO required more hospital resources. Patients who achieved TO were more likely to remain free of chronic kidney disease (achieved TO, 83.8% [82.7-85.6]; failed TO, 67.9% [66.9-70.2]; P < .05). Tacrolimus dose and trough levels were similar. CONCLUSIONS A novel finding of our study is that short and medium-term kidney function is better preserved in patients who experience a TO. Better kidney function of patients who achieve TO is not due to lower tacrolimus dosage.
Collapse
Affiliation(s)
- Paola Melgar
- Hepato-Pancreato-Biliary Surgery and Liver Transplantation, General University Hospital of Alicante (HGUA), and Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain Hepatobiliary and Pancreas Surgery, Miami Cancer Institute, Miami, FL, USA Gastroenterology and Hepatology, General University Hospital of Alicante (HGUA), and Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain Nephrology, General University Hospital of Alicante (HGUA), and Health and Biomedical Research Institut of Alicant (ISABIAL), Alicante, Spain Pharmacy and Pharmacokinetics, General University Hospital of Alicante (HGUA), and Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain Clinical Pharmacology, General University Hospital of Alicante (HGUA), and Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Rodríguez-Laiz GP, Melgar-Requena P, Alcázar-López CF, Franco-Campello M, Villodre-Tudela C, Pascual-Bartolomé S, Bellot-García P, Rodríguez-Soler M, Miralles-Maciá CF, Más-Serrano P, Navarro-Martínez JA, Martínez-Adsuar FJ, Gómez-Salinas L, Jaime-Sánchez FA, Perdiguero-Gil M, Díaz-Cuevas M, Palazón-Azorín JM, Such-Ronda J, Lluís-Casajuana F, Ramia-Ángel JM. Fast-Track Liver Transplantation: Six-year Prospective Cohort Study with an Enhanced Recovery After Surgery (ERAS) Protocol. World J Surg 2021; 45:1262-1271. [PMID: 33620540 PMCID: PMC8026463 DOI: 10.1007/s00268-021-05963-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/27/2020] [Indexed: 01/14/2023]
Abstract
Introduction Enhanced recovery after surgery (ERAS) has been shown to facilitate discharge, decrease length of stay, improve outcomes and reduce costs. We used this concept to design a comprehensive fast-track pathway (OR-to-discharge) before starting our liver transplant activity and then applied this protocol prospectively to every patient undergoing liver transplantation at our institution, monitoring the results periodically. We now report our first six years results.
Patients and methods Prospective cohort study of all the liver transplants performed at our institution for the first six years. Balanced general anesthesia, fluid restriction, thromboelastometry, inferior vena cava preservation and temporary portocaval shunt were strategies common to all cases. Standard immunosuppression administered included steroids, tacrolimus (delayed in the setting of renal impairment, with basiliximab induction added) and mycophenolate mofetil. Tacrolimus dosing was adjusted using a Bayesian estimation methodology. Oral intake and ambulation were started early.
Results A total of 240 transplants were performed in 236 patients (191♂/45♀) over 74 months, mean age 56.3±9.6 years, raw MELD score 15.5±7.7. Predominant etiologies were alcohol (n = 136) and HCV (n = 82), with hepatocellular carcinoma present in 129 (54.7%). Nine patients received combined liver and kidney transplants. The mean operating time was 315±64 min with cold ischemia times of 279±88 min. Thirty-one patients (13.1%) were transfused in the OR (2.4±1.2 units of PRBC). Extubation was immediate (< 30 min) in all but four patients. Median ICU length of stay was 12.7 hours, and median post-transplant hospital stay was 4 days (2-76) with 30 patients (13.8%) going home by day 2, 87 (39.9%) by day 3, and 133 (61%) by day 4, defining our fast-track group. Thirty-day-readmission rate (34.9%) was significantly lower (28.6% vs. 44.7% p=0.015) in the fast-track group. Patient survival was 86.8% at 1 year and 78.6% at five years. Conclusion Fast-Tracking of Liver Transplant patients is feasible and can be applied as the standard of care
Collapse
Affiliation(s)
- Gonzalo P Rodríguez-Laiz
- Hepatobiliary Surgery and Liver Transplantation, Hospital General Universitario de Alicante, Alicante, Spain.
- ISABIAL (Alicante Institute for Health and Biomedical Research, Alicante, Spain.
| | - Paola Melgar-Requena
- Hepatobiliary Surgery and Liver Transplantation, Hospital General Universitario de Alicante, Alicante, Spain
- ISABIAL (Alicante Institute for Health and Biomedical Research, Alicante, Spain
| | - Cándido F Alcázar-López
- Hepatobiliary Surgery and Liver Transplantation, Hospital General Universitario de Alicante, Alicante, Spain
- ISABIAL (Alicante Institute for Health and Biomedical Research, Alicante, Spain
| | - Mariano Franco-Campello
- Hepatobiliary Surgery and Liver Transplantation, Hospital General Universitario de Alicante, Alicante, Spain
| | - Celia Villodre-Tudela
- Hepatobiliary Surgery and Liver Transplantation, Hospital General Universitario de Alicante, Alicante, Spain
- ISABIAL (Alicante Institute for Health and Biomedical Research, Alicante, Spain
| | - Sonia Pascual-Bartolomé
- Hepatology and Liver Unit, Hospital General Universitario de Alicante, Alicante, Spain
- ISABIAL (Alicante Institute for Health and Biomedical Research, Alicante, Spain
| | - Pablo Bellot-García
- Hepatology and Liver Unit, Hospital General Universitario de Alicante, Alicante, Spain
- ISABIAL (Alicante Institute for Health and Biomedical Research, Alicante, Spain
| | - María Rodríguez-Soler
- Hepatology and Liver Unit, Hospital General Universitario de Alicante, Alicante, Spain
- ISABIAL (Alicante Institute for Health and Biomedical Research, Alicante, Spain
| | - Cayetano F Miralles-Maciá
- Hepatology and Liver Unit, Hospital General Universitario de Alicante, Alicante, Spain
- ISABIAL (Alicante Institute for Health and Biomedical Research, Alicante, Spain
| | - Patricio Más-Serrano
- Pharmacy and Pharmacokinetics, Hospital General Universitario de Alicante, Alicante, Spain
- ISABIAL (Alicante Institute for Health and Biomedical Research, Alicante, Spain
| | - José A Navarro-Martínez
- Anesthesiology and Surgical Critical Care, Hospital General Universitario de Alicante, Alicante, Spain
| | | | - Luis Gómez-Salinas
- Anesthesiology and Surgical Critical Care, Hospital General Universitario de Alicante, Alicante, Spain
- ISABIAL (Alicante Institute for Health and Biomedical Research, Alicante, Spain
| | | | - Miguel Perdiguero-Gil
- Nephrology and Renal Transplantation, Hospital General Universitario de Alicante, Alicante, Spain
- ISABIAL (Alicante Institute for Health and Biomedical Research, Alicante, Spain
| | - María Díaz-Cuevas
- Nephrology and Renal Transplantation, Hospital General Universitario de Alicante, Alicante, Spain
- ISABIAL (Alicante Institute for Health and Biomedical Research, Alicante, Spain
| | | | - José Such-Ronda
- Digestive Disease Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
| | | | - José M Ramia-Ángel
- Hepatobiliary Surgery and Liver Transplantation, Hospital General Universitario de Alicante, Alicante, Spain
- ISABIAL (Alicante Institute for Health and Biomedical Research, Alicante, Spain
| |
Collapse
|
3
|
Rodríguez-Laiz GP, Melgar P, Alcázar-López C, Franco-Campello M, Martínez-Adsuar F, Navarro-Martínez J, Gómez-Salinas L, Pascual S, Bellot P, Carnicer F, Rodríguez-Soler M, Palazón JM, Mas-Serrano P, Almanza-López S, Jaime-Sánchez F, Perdiguero M, de Santiago C, Lozano T, Irurzun J, Pérez E, Merino E, Zapater P, Lluís F. Enhanced recovery after low- and medium-risk liver transplantation. A single-center prospective observational cohort study. Int J Surg 2020; 85:46-54. [PMID: 33338651 DOI: 10.1016/j.ijsu.2020.12.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Revised: 11/26/2020] [Accepted: 12/11/2020] [Indexed: 01/30/2023]
Abstract
BACKGROUND & AIMS Few studies have fully applied an enhanced recovery after surgery (ERAS) protocol to liver transplantation (LT). Our aim was to assess the effects of a comprehensive ERAS protocol in our cohort of low- and medium-risk LT patients. METHODS The ERAS protocol included pre-, intra-, and post-operative steps. During the five-year study period, 181 LT were performed in our institution. Two cohorts were identified: low risk patients (n = 101) had a laboratory model for end-stage liver disease (MELD) score of 20 points or less at the time of LT, received a liver from a donor after brain death, and had a balance of risk score of 9 points or less; medium-risk patients (n = 15) had identical characteristics except for a higher MELD score (21-30 points). In addition, we analyzed the remaining patients (n = 65) who were transplanted over the same study period separately using the ERAS protocol. RESULTS The low-risk cohort showed a low need for packed red blood cells transfusion (median: 0 units) and renal replacement therapy (1%), as well as a short length of stay both in the intensive care unit (13 h) and in the hospital (4 days); morbidity during one-year follow-up, and probability of surviving to one year (89.30%) and five years (76.99%) were in line with well-established reference data. Similar findings were observed in the medium-risk cohort. CONCLUSIONS This single-center prospective observational cohort study provides evidence that ERAS is feasible and safe for low- and medium-risk LT.
Collapse
Affiliation(s)
- Gonzalo P Rodríguez-Laiz
- Hepatopancreatobiliary Surgery and Liver Transplantation, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - Paola Melgar
- Hepatopancreatobiliary Surgery and Liver Transplantation, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain.
| | - Cándido Alcázar-López
- Hepatopancreatobiliary Surgery and Liver Transplantation, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - Mariano Franco-Campello
- Hepatopancreatobiliary Surgery and Liver Transplantation, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - Francisco Martínez-Adsuar
- Anesthesiology and Surgical Critical Care, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - José Navarro-Martínez
- Anesthesiology and Surgical Critical Care, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - Luís Gómez-Salinas
- Anesthesiology and Surgical Critical Care, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - Sonia Pascual
- Gastroenterology and Hepatology, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - Pau Bellot
- Gastroenterology and Hepatology, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - Fernando Carnicer
- Gastroenterology and Hepatology, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - María Rodríguez-Soler
- Gastroenterology and Hepatology, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - José M Palazón
- Gastroenterology and Hepatology, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - Patricio Mas-Serrano
- Pharmacy and Pharmacokinetics, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - Susana Almanza-López
- Critical Care Medicine, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - Francisco Jaime-Sánchez
- Critical Care Medicine, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - Miguel Perdiguero
- Nephrology, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - Carlos de Santiago
- Transplant Coordination, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - Teresa Lozano
- Cardiology, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - Javier Irurzun
- Radiology, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - Enrique Pérez
- Psychiatry, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - Esperanza Merino
- Infectious Diseases, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - Pedro Zapater
- Clinical Pharmacology, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| | - Félix Lluís
- Hepatopancreatobiliary Surgery and Liver Transplantation, General University Hospital of Alicante (HGUA), And Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain
| |
Collapse
|